Clinical trials: Chronic Graft vs. Host Disease
Chronic Graft-versus-host-disease
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received…
- Trial name
- AGAVE-201 (NCT04710576)
- Testing
- Axatilimab
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Syndax Pharmaceuticals
Graft vs Host Disease
Extracorporeal Photopheresis to Treat Chronic Graft-Versus-Host Disease
This study will examine the safety and effectiveness of extracorporeal photopheresis (ECP) for treating chronic graft-versus-host disease (GvHD).
- Trial name
- NCT00048789
- Testing
- Extracorporeal Photopheresis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease
Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease
This study will investigate the safety and effectiveness of a modified stem cell transplant procedure for treating chronic granulomatous disease (CGD) in patients with active infection.
- Trial name
- NCT00001765
- Testing
- Nexell Isolex with T-cell Depletion, Baxter isolex 300i
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil (MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in patients undergoing donor stem cell…
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma
- Trial name
- NCT00105001
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 210 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft Versus Host Disease in Eye
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease.
- Trial name
- NCT05294666
- Testing
- Cyclosporine, tacrolimus
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Peking University Third Hospital
Graft vs Host Disease
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and…
- Trial name
- NCT03474679
- Testing
- Ibrutinib
- Where
- 15 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Graft Versus Host Disease, Leukemia
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against normal tissues.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00002456
- Testing
- cyclosporine, methotrexate, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Graft-Versus-Host Disease, GVHD
Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease
Graft-versus-host-disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT) which may cause acute life-threatening morbidity or chronic disabilities.
- Conditions
- Graft-Versus-Host Disease, GVHD, Allogeneic Hematopoietic Transplant, Disorder Related to Transplantation
- Trial name
- GVHD-MSC (NCT01549665)
- Testing
- Human umbilical cord blood-derived mesenchymal stem cells
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Graft Versus Host Disease, Leukemia
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00014469
- Testing
- busulfan, melphalan, methotrexate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft Versus Host Disease, JNS Kinase
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
Background: About half the people who have a hematopoietic stem cell transplant using donor cells get Chronic Graft Versus Host Disease (cGVHD). This is chronic graft versus host disease.
- Conditions
- Graft Versus Host Disease, JNS Kinase, Topical Administration
- Trial name
- NCT03395340
- Testing
- Ruxolitinib 1.5% cream, vehicle cream
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Chronic Myelogenous Leukemia
Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in…
- Trial name
- LASOR (NCT00802841)
- Testing
- nilotinib, imatinib
- Where
- 56 sites in Argentina, Brazil and 10 more
- Volunteers
- 191 people
- Sponsor
- Novartis Pharmaceuticals
Graft Versus Host Disease
Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease
Study Design: Treatment, Randomized, Open Label, Parallel Assignment,Safety/Efficacy Study. The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSC) expanded ex-vivo infusion for the…
- Trial name
- NCT00972660
- Testing
- Mesenchymal stem cell (MSC), Prednisone and cyclosporine or primary therapies
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Guangdong Provincial People's Hospital
Chronic Graft Versus Host Disease
Improving Outcomes Assessment in Chronic GVHD
The purpose of this study is to see if recent guidelines proposed by the National Institutes of Health for the diagnosis, staging, and response assessment of people with chronic GVHD can improve our understanding of this…
- Trial name
- NCT00637689
- Where
- 9 sites in United States
- Volunteers
- 601 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancies
Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
This is a randomized trial for patients undergoing hematopoietic progenitor cell transplantation (HPCT) from an unrelated donor.
- Trial name
- NCT01217723
- Testing
- Anti-Thymocyte Globulin (Rabbit), Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)
- Where
- 10 sites in Canada
- Volunteers
- 198 people
- Sponsor
- McMaster University
Graft Vs Host Disease
Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease
cGVHD is a systemic disease with multi-system damage similar to autoimmune and other immune diseases. It can affect multiple organs such as skin, liver, kidney, and peripheral nerves, causing a serious decline in the quality of…
- Trial name
- NCT05152160
- Testing
- Umbilical Cord Mesenchymal Stem Cell Therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Hepatitis B Virus Infection, Children
Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-tolerant, HBeAg-positive children aged 3-6 years with…
- Conditions
- Hepatitis B Virus Infection, Children, Chronic Hepatitis B
- Trial name
- NCT07345624
- Testing
- Entecavir, Entecavir + Pegylated interferon α-2b
- Volunteers
- 80 people
- Sponsor
- Qing-Lei Zeng
Oral Disease, Graft-versus-host-disease
Prevalence of Chronic Oral Graft Versus Host Disease Risk Factors in Pediatric Patients
our aim is estimating the Prevalence and predicting risk factors for developing chronic oral graft versus host disease in pediatric patients subjected to hematopoietic stem cells transplantation
- Conditions
- Oral Disease, Graft-versus-host-disease, Stem Cell Transplant Complications, Pediatric Disorder
- Trial name
- NCT03880214
- Volunteers
- 250 people
- Sponsor
- yasmeen magdi sholkamy
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
T-cell Depleted Alternative Donor Transplantation
The primary purpose is to determine the ability of CD34+ selection and T cell depletion using the CliniMACS® device to prevent severe acute graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from an…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00968864
- Testing
- CliniMACS® (T cell depletion)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Wake Forest University Health Sciences